宝元可以通过抑制过氧化脂肪酸和Src/MKK4/JNK通路介导的CD 36表达来抑制动脉样硬化进展
Zhen Wu1, Lingxiao Wang2, Ziyu Yin2
1Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
概括
宝元 (BYD) 显示出通过减少斑块负担来治疗动脉样硬化的潜力. 它通过降低巨细胞中CD36表达的调节来抑制泡细胞的形成,提供了一种新的治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 传统中国医药 传统中国医药
- 代谢学 代谢学 代谢学
背景情况:
- (Baoyuan decoction,简称BYD) 是一种用于治疗各种疾病的传统药物.
- 它对动脉样硬化的疗效仍然未被探索.
研究的目的:
- 评估比亚迪作为动脉样硬化抑制剂的潜力.
- 为了研究比亚迪在防止泡细胞形成的机制.
主要方法:
- 在使用高脂肪饮食的ApoE-/-小鼠中诱导了动脉样硬化.
- 使用LC-Qtrap-MS分析了便差异代谢物.
- 研究了BYD对THP-1巨细胞中oxLDL诱导的泡细胞形成的影响.
主要成果:
- 在未改变血脂质的情况下,BYD治疗减少了小鼠的动脉样硬化斑块负担.
- 由BYD抑制的便过氧化脂肪酸,包括9/13-氧十三甲酸 (9/13-HODE).
- BYD通过Src/MMK4/JNK通路抑制了巨细胞中oxLDL诱导的CD36过度表达,减少了脂质沉积.
结论:
- 比亚迪证明了抗动脉样硬化作用.
- BYD通过降低CD36表达的调节来抑制泡细胞的形成.
相关概念视频
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747